Nancy Lurker was appointed the Company's President & Chief Executive Officer in September 2016. Ms. Lurker has had broad ranging experience in the pharmaceutical industry and companies serving the pharmaceutical industry, including diverse senior leadership positions. From 2008 to 2015, Ms. Lurker served as President and Chief Executive Officer and a Director of PDI, Inc., a NASDAQ-listed healthcare commercialization company. She successfully rebuilt PDI's contract sales business, launching numerous pharmaceutical products for multiple companies across diverse therapeutic areas, including ophthalmology, in advance of a sale of that business line to Publicis Healthcare Communications Group and then repositioned the company as the higher growth, higher margin molecular diagnostics business now named Interpace Diagnostics Group, Inc. From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG, where she oversaw a multi-billion-dollar product portfolio covering cardiovascular, bone, pain, urology, respiratory, dermatology, biologics, neurology and metabolic therapeutic areas. From 2003 to 2006, she served as President and Chief Executive Officer of Impact Rx, Inc., a privately held healthcare information company, now part of IMS Health Holdings, Inc., where she substantially grew revenues and profitability. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation, where she led a global business unit that commercialized urology, cardiovascular, central nervous system, respiratory and women's health drugs, overseeing the worldwide launch of Detrol and Detrol LA and repositioning Ambien for revenue growth. She also served as a member of Pharmacia's U.S. executive management committee. Previously, Ms. Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Ms. Lurker previously served as a member of the Board of Directors of Mallinckrodt Pharmaceuticals,plc (NYSE: MNK) and Auxilium Pharmaceuticals,Inc. (NASDAQ: ENDP). Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.
David Price has served as EyePoint’s Chief Financial Officer since August 2018. Mr. Price brings to EyePoint more than 25 years of financial experience in the healthcare, investment banking and accounting industries. He has extensive experience in executing debt and equity capital financings, business development deals, restructurings and oversight of all financial functions in both domestic and international markets for public and private commercial companies.
Most recently, he served as Chief Financial Officer of Concordia International Corporation, a publicly traded, revenue generating, generic pharmaceutical company. Prior to Concordia, he was the Chief Financial Officer at Bioventus, a global, commercial medical device company, where he was responsible for the creation of an independent business unit following the company’s spinout from Smith & Nephew. In this role, he led a $175 million debt financing and $210 million public debt raise. In addition, Mr. Price served as Chief Financial Officer of Cornerstone Therapeutics Inc., a publicly-traded, commercial specialty pharmaceutical company, where he orchestrated and executed the reverse merger of Cornerstone BioPharma with Critical Therapeutics to form Cornerstone Therapeutics Inc. Mr. Price also served as Chief Financial Officer of EDGAR Online, Inc., a financial data, technology and business process outsourcing company.
In addition to his corporate experience, Mr. Price previously served as a managing director in the healthcare and pharmaceutical services sector at both Jefferies & Company and Bear Stearns & Co. Mr. Price began his career in public accounting at Arthur Andersen and PriceWaterhouseCoopers, and earned a B.A. in Accounting from Lancaster University.
Jack Weet has served as EyePoint’s Senior Vice President, Regulatory Affairs & Quality since August 2018. Dr. Weet brings to EyePoint over 40 years of experience in regulatory affairs. He has extensive expertise in the oversight of U.S. Food and Drug Administration relations and negotiations across multiple therapeutic areas, including ocular disease.
Prior to joining EyePoint, Dr. Weet served as Vice President, Regulatory Affairs and Quality Assurance at Collegium Pharmaceutical, a commercial stage specialty pharmaceutical company focused on pain management, where he was responsible for overall regulatory direction and development of standard practices, procedures and regulatory operations, and worked closely on the approval for XTAMPZA® ER, an extended-release, abuse-deterrent opiate. Prior to Collegium, Dr. Weet was Vice President, Regulatory Affairs at Durata Therapeutics (acquired by Actavis plc) and Vertex Pharmaceuticals, where he worked on the regulatory submission of Dalvance® (dalbavancin) and Incivek® (telaprevir), respectively. He also previously served as Vice President, Global Regulatory Affairs at Bausch + Lomb, a wholly owned subsidiary of Bausch Health focused on the treatment and prevention of diseases of the eye, where he oversaw global regulatory affairs for the company’s pharmaceutical business. In this role, Dr. Weet worked on the regulatory submission for Besivance® (besifloxacin) for the treatment of bacterial conjunctivitis. Prior to joining Bausch + Lomb, he served in various regulatory affairs positions at numerous pharmaceutical companies including Biovail Technologies, Ltd., Novartis Pharmaceuticals, and Solvay Pharmaceuticals.
In addition to his industry experience, Dr. Weet has served on the faculty of the Pharmaceutical Education and Research Institute (PERI), as a guest lecturer at Georgia Institute of Technology, a member of the Long Island University Curriculum Planning Committee of the Arnold and Marie Schwartz College of Pharmacy, and has authored various papers and presentations at industry conferences.
Dr. Weet received a B.S. in Psychology from St. Lawrence University, and a Ph.D. in Physiology from the Ohio State University College of Medicine. He completed his postdoctoral fellowship at the University of Iowa College of Medicine.
Mr. Nazzaro has served as the Company's Vice President of Operations since November 2009 having previously served as Director of Operations from May 2006 to November 2009. Mr. Nazzaro is the former Director of Manufacturing for Control Delivery Systems. Prior to CDS, Mr. Nazzaro held a variety of positions with Boston Scientific Corporation including responsibilities in logistics, R&D, manufacturing and distribution, including responsibility for distribution of cardiac care devices. Mr. Nazzaro has over 20 years of product life cycle and operations experience. Mr. Nazzaro received a Bachelor of Science degree in Accounting from Suffolk University in Boston, MA.
Dr. Paggiarino joined EyePoint Pharmaceuticals from Lpath, a leader in lipid-targeted therapeutics, where he served as senior vice president and chief development officer. Prior to joining Lpath, he was vice president and therapeutic unit head for retina diseases at Alcon Laboratories, a division of Novartis, where he was responsible for advancing its retina pharmaceutical development pipeline through regulatory approvals worldwide. Dr. Paggiarino previously served as executive director of clinical development and medical affairs at Pfizer Global R&D, with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases and medical responsibilities for Macugen®, the first anti-VEGF treatment approved for age-related macular degeneration. Earlier in his career he held research and development positions at Angelini Pharmaceuticals, a private company, where he advanced to president of the firm, and Pharmacia Global R&D, where he was clinical program director of ophthalmology with responsibilities including Xalatan®, one of the leading glaucoma therapies in the world. Dr. Paggiarino earned his degree in Medicine and General Surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.
Ron Honig, Esq., has served as EyePoint’s Senior Vice President, General Counsel and Company Secretary since November 2018. Mr. Honig brings to EyePoint more than 25 years of legal experience in the medical device, biotechnology, contract manufacturing and legal services industries. As lead in-house counsel to publicly-traded companies and private equity portfolio companies in the global healthcare industry, Mr. Honig has managed legal and compliance functions and has had responsibility with a wide variety of business transactions.
Most recently, Mr. Honig served as VP, Global Legal Affairs for Novanta Inc., a publicly-traded company that develops and manufactures technology solutions for medical device and advanced industrial equipment makers worldwide. Prior to Novanta, he was the Senior Vice President, General Counsel & Company Secretary of Lake Region Medical, a privately-held medical device and medical component manufacturer, where he was responsible for all legal, intellectual property and environmental, health and safety functions worldwide. In addition, Mr. Honig served as Vice President, Group Legal Affairs and Company Secretary for Gyrus ACMI, a publicly-traded medical device manufacturer focused on urological and gynecological endoscopes, digital visualization and endoscopic treatment and delivery modalities.
In addition to his in-house legal experience, Mr. Honig previously served as a corporate attorney for several law firms, including Mintz Levin Cohn Ferris Glovsky and Popeo in Boston. He earned his Juris Doctor degree from Boston University, where he served as Editor-In-Chief of the Boston University Law Review, and earned a Bachelor of Science in Finance from the Wharton School and a Bachelor of Applied Science in Systems Engineering from the School of Engineering at the University of Pennsylvania.
Mr. Ross has served as the Company's Vice President of Finance since November 2009 and was previously Corporate Controller from October 2006. Mr. Ross was designated as the Company's Principal Financial and Accounting Officer in March 2009. Mr. Ross is the former Corporate Controller of NMT Medical, Inc. and previously served as Vice President of Finance and Vice President of International Operations for JetForm Corporation. Mr. Ross brings 30 years of accounting and financial management experience to the Company. Mr. Ross received a Bachelor of Science degree in Chemical Engineering from Tufts University and an MBA from the Amos Tuck School at Dartmouth College.
Dr. Riedel joined EyePoint Pharmaceuticals in October 2011, bringing with him over 29 years of biopharmaceutical R&D experience. Dr. Riedel has contributed significantly to the achievement of regulatory approval of several novel product candidates, including: INFUSE® (dibotermin alfa); Plenaxis® (abarelix), and the first generic version of Lovenox® (enoxaparin sodium). Dr. Riedel has previously served as Vice President, Regulatory Affairs and Program Management at NormOxys, Inc., as Vice President of Regulatory Affairs at Momenta Pharmaceuticals and as Senior Vice President of Regulatory Affairs, Quality Assurance and Project Management at PRAECIS Pharmaceuticals, Inc. Before joining PRAECIS, Dr. Riedel held various senior R&D positions at Wyeth Research and Genetics Institute, Inc. Dr. Riedel received a B.A. degree in Biochemical Sciences from Harvard College and a Ph.D. in Biology from Harvard University.
Dr. Guo has served as the Company's Vice President of Research since November 2009 having previously served as Director of Research from January 2006 to November 2009. Prior to joining EyePoint Pharmaceuticals, Dr. Guo served as the Director of Preformulation and as a Senior Scientist for Control Delivery Systems where she was one of the original inventors of Durasert sustained release drug delivery system. Prior to joining CDS, Dr. Guo was a Post-Doctoral Research Scientist at New England Eye Center and at the University of Kentucky. Dr. Guo received Masters of Science in Medicinal Chemistry and a Bachelor of Science degree in Pharmacy from China Pharmaceutical University and Ph.D. in Medicinal Chemistry from the University of Heidelberg.